Latest Conference Articles

Disha Patel, PharmD, discusses current data on G-CSF use during HiDAC consolidation for AML, addressing relapse concerns, infection risk, clinical decision-making, and why practice patterns remain divided across institutions.

Ahead of the Sports Pharmacy Summit, a pharmacist weighs GLP-1s for athlete weight management benefits.

From bispecifics to real-world evidence, Amy Seung previews the science, community, and advocacy opportunities defining this year's meeting.

New AAAAI data spotlight oral remibrutinib for CSU, next-generation peanut allergy therapies, infant microbiome prevention, and GLP‑1 receptor agonists linked to fewer asthma flares.

VOYAGE trial data show dupilumab improves pediatric asthma control and lowers exacerbations versus placebo, with higher remission and lung function gains earlier.

Wildfire smoke exposure increases asthma morbidity, underscoring the pharmacist’s role in medication preparedness and patient education.

Phase 2 trial data support the safety and efficacy of remibrutinib in adults with peanut allergy.

Emerging skin lipid biomarkers precede atopic dermatitis and food allergy, emphasizing barrier restoration as a key therapeutic target for pharmacists.

Remibrutinib is the first oral advanced therapy for adults with chronic spontaneous urticaria (CSU) who remain uncontrolled on high-dose second-generation antihistamines.

AAAAI 2026 highlights STMC-103H live biotherapeutic, showing reduced atopic disease risk in at-risk infants—potentially an early microbiome intervention for atopic dermatitis and food allergy.

Careful history, adherence support, and proper medication technique are central to diagnosing and managing chronic cough in children.

Social determinants of health and environmental exposures during extreme weather events worsen asthma outcomes.

Emerging targets are reshaping how mCRPC is treated, as showcased at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium.

Remibrutinib, an oral Bruton tyrosine kinase inhibitor for chronic spontaneous urticaria (CSU), delivers itch and hive relief within 12 hours and sustains improvements through week 1.

Data presented at AAAAI 2026 show tapinarof cream improves sleep for children as young as 2 years with atopic dermatitis, easing nighttime disruption.

Data presented at the 2026 ASCO Genitourinary Cancers Symposium show the benefit of enfortumab vedotin-ejfv plus pembrolizumab in muscle-invasive bladder cancer.

Capivasertib plus abiraterone improves survival in PTEN-deficient hormone-sensitive prostate cancer.

PEACE-3 trial data presented at ASCO GU show survival benefits with enzalutamide combination.

Experts discuss the role of pharmacists in CAR T-cell and gene therapy at the 2026 ASTCT Tandem Meeting in Salt Lake City.

Pharmacists enhance health care delivery by managing medication refills, addressing drug shortages, and supporting chronic disease management.

Explore the evolving landscape of health care market access, cash models, and innovative pharmacy distribution strategies shaping the future of pharmaceuticals.

New research highlights the efficacy and safety of HRS-1780, an investigational nonsteroidal MRA, in treating chronic kidney disease (CKD).

Sacituzumab govitecan shows promising overall survival trends in HR+/HER2− metastatic breast cancer, despite not meeting primary progression-free survival goals.

Sarah J. Billups, PharmD, highlights the disconnect between medication adherence metrics and actual patient outcomes, urging a reevaluation of adherence measures in health care.

Prateek Bhatia discusses optimizing staffing and workflows in infusion centers to enhance patient care and reduce delays in treatment.

IV compounding robotics and next-generation dispensing technology enhance pharmacy workflows, boost staff engagement, and improve patient care outcomes.

Ribociclib shows higher early treatment modifications than palbociclib in HR+/HER2– breast cancer, emphasizing the need for proactive toxicity management.